A voluntary agreement between the Government and the pharmaceutical industry.
The relationship between the pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in the development and delivery of life-enhancing and life-saving medicines.
The Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) have welcomed the publication of "Continuity in the availability of goods for the EU and the UK", published today by the UK Government's Department for Exiting the European Union.
As a membership organisation we work with our member companies, and the expertise of the specialists they employ, to develop and present our points of view to UK and European governments, the public and to other stakeholders.
ABPI and BIVDA are holding the third biopharma-diagnostics networking event 'Generating a NICE assessment for stratified medicines'.
The event will open with scene-setting perspectives on Health Technology Assessment for personalised medicines from our confirmed speakers:
• Adrian Newland, Chair, NICE Diagnostics Advisory Committee• Greg Rossi, Vice-President, Payer & Real World Evidence, AstraZeneca • Berwyn Clarke, Chairman, NALIA Systems Ltd
These will be followed by a panel session, when the speakers will take questions from the audience. Discussion will continue over networking and drinks.
When? Monday 20 January 2014, 4.30-7.30pmWhere? Central London venue to be confirmed
To reserve your place, please email Ivan Dennie, ABPI Events Manager, email@example.com